Daily Cardiology Research Analysis
Analyzed 173 papers and selected 3 impactful papers.
Summary
Three studies stood out in cardiology: a single-center randomized trial showed distal transradial access (dTRA) for PCI markedly reduces radial artery occlusion and halves hemostasis time versus conventional transradial access. A meta-analysis across 17,116 AF patients found left atrial appendage closure lowers mortality and composite outcomes versus oral anticoagulants with similar stroke and major bleeding. An observational cohort linked OCT-guided PCI in acute MI to reduced 1-year heart failure, supporting intravascular imaging in emergent revascularization.
Research Themes
- Vascular access optimization for PCI
- Device-based stroke prevention versus anticoagulation in AF
- Imaging-guided reperfusion in acute myocardial infarction
Selected Articles
1. Distal transradial access for percutaneous coronary intervention: a single-center randomized controlled study (DRAGON study).
In a randomized, open-label trial of 425 elective PCI patients, dTRA reduced 24-hour RAO from 8.7% to 0.5% and 30-day RAO from 8.2% to 1.6% versus conventional TRA. Hemostasis time was halved (3 h vs 6 h) without differences in procedural success or radiation exposure, and early wrist function was slightly better.
Impact: This RCT provides robust evidence that dTRA improves access-site outcomes without trade-offs, directly informing PCI access strategy.
Clinical Implications: Programs can consider adopting dTRA as default access for elective PCI with training and protocols to standardize duplex-confirmed RAO surveillance and shorter hemostasis strategies.
Key Findings
- 24-hour RAO: 0.5% with dTRA vs 8.7% with TRA (p<0.001).
- 30-day RAO: 1.6% with dTRA vs 8.2% with TRA (p<0.001).
- Hemostasis time reduced from 6.0 h (TRA) to 3.0 h (dTRA), with similar procedural success (82.2% vs 80.2%) and radiation exposure.
Methodological Strengths
- Prospective randomized allocation with predefined endpoints and duplex ultrasound assessment of RAO.
- Comprehensive secondary outcomes including hemostasis time, radiation exposure, and functional scores.
Limitations
- Single-center, open-label design may limit generalizability.
- Short follow-up (30 days) without long-term radial patency or access re-use outcomes.
Future Directions: Multicenter RCTs with longer follow-up to assess long-term patency, dialysis access preservation, cost-effectiveness, and performance in acute coronary syndromes.
BACKGROUND: Transradial access (TRA) is the standard vascular approach for coronary interventions because it lowers bleeding risk and improves patient comfort. Nevertheless, radial artery occlusion (RAO) remains an important limitation, preventing re-use of the radial artery for subsequent procedures. Distal transradial access (dTRA) has been proposed as a strategy to further reduce RAO while preserving procedural efficacy. AIMS: To assess whether dTRA reduces early and mid-term RAO compared with conventional TRA in patients undergoing percutaneous coronary intervention (PCI). METHODS: In this single-center, prospective, randomized, open-label superiority trial, 426 consecutive patients scheduled for elective PCI between July 2023 and January 2024 were assigned 1:1 to dTRA (n = 213) or TRA (n = 213). Duplex ultrasonography was used to assess RAO at 24 h and 30 days. PRIMARY ENDPOINT: 24-hour RAO; secondary endpoints: 30-day RAO, procedural success, hemostasis time, radiation exposure, and hand/wrist function scores. RESULTS: One patient withdrew consent, leaving 425 patients (dTRA 213, TRA 212) for analysis. The 24-hour RAO rate was significantly lower in the dTRA group compared to the TRA group (0.5% vs. 8.7%, p < 0.001). At 30 days, RAO remained lower in the dTRA group (1.6% vs. 8.2%, p < 0.001). Median hemostasis time was 3.0 h with dTRA versus 6.0 h with TRA (p < 0.001). Procedural success was comparable between groups (82.2% vs. 80.2%; p = 0.72), as was the fluoroscopy dose (1630.0 mGy [1069.0-2481.0] vs. 1598.0 mGy [1039.0-2512.0], p = 0.73). Early wrist function scores were marginally better in the dTRA group (p = 0.048). CONCLUSIONS: In elective PCI patients, dTRA significantly reduces RAO incidence and shortens hemostasis time compared to TRA, without compromising procedural success or increasing radiation exposure, while modestly improving early hand function. These data support routine adoption of dTRA for coronary interventions. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2300073902 (registered on 25 July 2023).
2. Left Atrial Appendage Closure Versus Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Across 15 studies (17,116 AF patients), LAA closure reduced mortality and a composite clinical endpoint compared with oral anticoagulants, with similar risks of stroke and major bleeding. Findings suggest LAA closure is a reasonable alternative, especially when long-term anticoagulation is unsuitable.
Impact: By synthesizing RCTs and robust observational cohorts, this analysis clarifies comparative effectiveness and safety, directly informing stroke prevention strategies in AF.
Clinical Implications: Consider LAA closure for AF patients at high bleeding risk, poor anticoagulation adherence, or contraindications to long-term OAC, using shared decision-making and structured post-procedural antithrombotic protocols.
Key Findings
- Meta-analysis of 15 studies (n=17,116) showed LAA closure reduced the composite endpoint vs OAC (RR 0.79; 95% CI 0.66–0.95).
- Mortality was lower with LAA closure, while stroke and major bleeding risks were similar to OAC.
- Evidence included 4 RCTs and multiple propensity-matched cohorts, increasing robustness.
Methodological Strengths
- Systematic search across four major databases with inclusion of RCTs and propensity-matched studies.
- Random-effects modeling accommodating between-study heterogeneity.
Limitations
- Heterogeneity in devices, antithrombotic regimens, and follow-up across studies.
- Observational data introduce residual confounding despite matching.
Future Directions: Head-to-head RCTs versus contemporary DOAC strategies, standardized post-LAAO antithrombotic protocols, and longer-term device durability and stroke outcomes.
BACKGROUND: Left atrial appendage (LAA) closure is an alternative to oral anticoagulants (OAC) for stroke prevention in atrial fibrillation (AF), but comparative evidence remains inconsistent. This study systematically evaluates the efficacy and safety of LAA closure versus OAC in AF patients. METHODS: We systematically searched PubMed, EmBase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and propensity score-matched (PSM) studies published up to 30 September 2025. Treatment effects were estimated using relative risks (RR) with 95% confidence intervals (CI), and a random-effects model was applied for all analyses. RESULTS: Fifteen studies (17,116 AF patients) were included, comprising 4 RCTs, 3 prospective PSM studies, and 8 retrospective PSM studies. Compared with OAC, LAA closure significantly reduced the composite endpoint (RR: 0.79; 95% CI: 0.66-0.95; CONCLUSIONS: In AF patients, LAA closure significantly reduces mortality and a composite clinical endpoint compared to OAC, with similar risks of stroke and major bleeding. It is a favorable alternative for patients unsuitable for long-term anticoagulation.
3. The Impact of Optical Coherence Tomography-Guided Percutaneous Coronary Intervention on 1-Year Heart Failure Events in Acute Myocardial Infarction Patients.
In 3,250 AMI patients undergoing PCI, OCT guidance was associated with a 22% lower adjusted risk of 1-year heart failure compared with angiography alone (HR 0.78). This supports the prognostic value of intravascular imaging in emergent reperfusion.
Impact: Links imaging-guided PCI to a clinically meaningful reduction in subsequent heart failure, a key determinant of long-term outcomes after MI.
Clinical Implications: Incorporate OCT guidance into AMI PCI workflows where available, particularly for optimization (plaque morphology, stent sizing/expansion), while pursuing systems-level evaluation of resource utilization.
Key Findings
- Observational cohort of 3,250 AMI patients: 1,901 OCT-guided vs 1,349 angiography-only.
- OCT guidance associated with lower 1-year heart failure risk after adjustment (HR 0.78; 95% CI 0.63–0.98; p=0.029).
- No other adjusted outcomes reported as significant, highlighting a specific benefit on heart failure.
Methodological Strengths
- Large real-world cohort with adjusted analyses to address baseline imbalances.
- Focus on patient-centered endpoint (1-year heart failure).
Limitations
- Non-randomized design risks selection bias and residual confounding.
- Details on imaging-driven strategy changes and standardized OCT criteria not provided.
Future Directions: Randomized trials testing OCT-guided PCI versus angiography in AMI with heart failure endpoints, and mechanistic studies on how imaging optimization translates to HF prevention.
BACKGROUND: Compared with angiography, there is limited evidence supporting the use of optical coherence tomography (OCT) guidance during percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). AIMS: The study aimed to evaluate the role of OCT in guiding reperfusion strategies and improving the prognosis of AMI patients. METHODS AND RESULTS: This was an observational cohort study of 3250 AMI patients who underwent PCI between September 1, 2016, and December 21, 2019 (1901 in the OCT group and 1349 in the non-OCT group). After adjusting for imbalanced variables in the groups, OCT group was only correlated with a markedly lower risk of HF (hazard ratio, 0.78; 95% CI, 0.63 to 0.98; p = 0.029). CONCLUSION: Compared with angiography alone, OCT guidance was associated with a lower incidence of HF in AMI patients at the 1-year follow-up.